HUT64848A - Medical preparatives for preventing and treating osteoporises after menopausa - Google Patents
Medical preparatives for preventing and treating osteoporises after menopausa Download PDFInfo
- Publication number
- HUT64848A HUT64848A HU9302183A HU9302183A HUT64848A HU T64848 A HUT64848 A HU T64848A HU 9302183 A HU9302183 A HU 9302183A HU 9302183 A HU9302183 A HU 9302183A HU T64848 A HUT64848 A HU T64848A
- Authority
- HU
- Hungary
- Prior art keywords
- ipriflavone
- estrogen
- treatment
- estrogens
- day
- Prior art date
Links
- 229960005431 ipriflavone Drugs 0.000 claims description 52
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 claims description 49
- 229940011871 estrogen Drugs 0.000 claims description 47
- 239000000262 estrogen Substances 0.000 claims description 47
- 229940035811 conjugated estrogen Drugs 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 24
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 claims description 9
- 206010027304 Menopausal symptoms Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 6
- 208000017657 Menopausal disease Diseases 0.000 claims description 5
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims description 4
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 2
- 239000007901 soft capsule Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 description 15
- 239000002775 capsule Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 229910052500 inorganic mineral Inorganic materials 0.000 description 10
- 239000011707 mineral Substances 0.000 description 10
- 235000012054 meals Nutrition 0.000 description 8
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010065687 Bone loss Diseases 0.000 description 5
- 208000001132 Osteoporosis Diseases 0.000 description 5
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 5
- 229960004127 naloxone Drugs 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229940057917 medium chain triglycerides Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000001457 vasomotor Effects 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000003687 estradiol congener Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000001592 luteinising effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 230000001836 utereotrophic effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000019222 white chocolate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI910253A IT1244697B (it) | 1991-02-01 | 1991-02-01 | Associazione farmaceutica per la prevenzione e il trattamento dell'osteoporosi post-menopausale |
Publications (2)
Publication Number | Publication Date |
---|---|
HU9302183D0 HU9302183D0 (en) | 1993-10-28 |
HUT64848A true HUT64848A (en) | 1994-03-28 |
Family
ID=11358374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9302183A HUT64848A (en) | 1991-02-01 | 1992-01-28 | Medical preparatives for preventing and treating osteoporises after menopausa |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0569415A1 (it) |
AU (1) | AU1188492A (it) |
CA (1) | CA2101547A1 (it) |
HU (1) | HUT64848A (it) |
IE (1) | IE920219A1 (it) |
IT (1) | IT1244697B (it) |
NZ (1) | NZ241418A (it) |
WO (1) | WO1992013538A1 (it) |
ZA (1) | ZA92661B (it) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0693927A4 (en) * | 1993-04-16 | 1997-05-28 | Univ Tufts Med | METHOD FOR TREATING MENAUPOSIC AND PREMENSTRUAL SYMPTOMS |
HU212932B (en) * | 1993-08-02 | 1996-12-30 | Chinoin Gyogyszer Es Vegyeszet | Parmaceutical composition containing ipriflavone, hydroxyapatit and tricalciumphosphate for treating lack of bones and process for producing the composition |
US6319914B1 (en) | 1993-11-05 | 2001-11-20 | Apollo Biopharmaceuticals, Inc. | Cytoprotective effect of polycyclic phenolic compounds |
US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
US5506211A (en) * | 1994-05-09 | 1996-04-09 | The Uab Research Foundation | Genistein for use in inhibiting osteroclasts |
US6326365B1 (en) | 1999-07-20 | 2001-12-04 | Apollo Biopharmaceutics, Inc. | Methods of prevention and treatment of ischemic damage |
US6339078B1 (en) | 1999-07-20 | 2002-01-15 | University Of Florida Research Foundation, Inc. | Methods of prevention and treatment of ischemic damage |
CA2441252A1 (en) * | 2001-03-16 | 2002-10-10 | Wyeth | Estrogen replacement therapy |
EP2081570A2 (en) | 2006-10-24 | 2009-07-29 | David W. Krempin | Anti-resorptive and bone building dietary supplements and methods of use |
-
1991
- 1991-02-01 IT ITMI910253A patent/IT1244697B/it active IP Right Grant
-
1992
- 1992-01-24 IE IE021992A patent/IE920219A1/en unknown
- 1992-01-27 NZ NZ241418A patent/NZ241418A/xx unknown
- 1992-01-28 EP EP92903484A patent/EP0569415A1/en not_active Ceased
- 1992-01-28 CA CA002101547A patent/CA2101547A1/en not_active Abandoned
- 1992-01-28 AU AU11884/92A patent/AU1188492A/en not_active Abandoned
- 1992-01-28 WO PCT/EP1992/000174 patent/WO1992013538A1/en not_active Application Discontinuation
- 1992-01-28 HU HU9302183A patent/HUT64848A/hu unknown
- 1992-01-30 ZA ZA92661A patent/ZA92661B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ZA92661B (en) | 1992-10-28 |
NZ241418A (en) | 1993-03-26 |
ITMI910253A0 (it) | 1991-02-01 |
WO1992013538A1 (en) | 1992-08-20 |
AU1188492A (en) | 1992-09-07 |
IE920219A1 (en) | 1992-08-12 |
ITMI910253A1 (it) | 1992-08-01 |
CA2101547A1 (en) | 1992-08-02 |
IT1244697B (it) | 1994-08-08 |
HU9302183D0 (en) | 1993-10-28 |
EP0569415A1 (en) | 1993-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3113269B2 (ja) | 骨粗鬆症治療剤 | |
DE602004002591T2 (de) | Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen | |
JP3208482B2 (ja) | 避妊製剤 | |
US4590213A (en) | Anti-anxiety method | |
JP2003095971A (ja) | 骨粗鬆症治療剤または組成物 | |
US4970237A (en) | Use of clomiphene to increase bone mass in premenopausal women | |
HUT64848A (en) | Medical preparatives for preventing and treating osteoporises after menopausa | |
AU2017206480B2 (en) | Composition, containing Loganin or a derivative thereof as an active ingredient for preventing, remedying, or treating female climacteric syndrome | |
EP3833370A1 (en) | Compositions for use in the treatment of obesity | |
US4820736A (en) | Use of clomiphene to predict fertility in a human female | |
Breslau | Calcium, estrogen, and progestin in the treatment of osteoporosis | |
AU2008235006A1 (en) | New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen | |
Nakamura et al. | Treatment of uterine leiomyomata with a luteinizing hormonereleasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women | |
Maddox | Women at midlife: Hormone replacement therapy | |
KR102225792B1 (ko) | 에키노크롬 a를 유효성분으로 함유하는 폐경기 증후군의 치료 또는 예방용 약학적 조성물 | |
US20220160734A1 (en) | Treatment of fibroids with vitamin d and an agent such as epigallocatechin gallate (egcg) | |
RU2220712C1 (ru) | Средство и набор для нормализации функциональных нарушений, возникающих в предклимактерический и климактерический период | |
JPH07109222A (ja) | 骨粗鬆症予防及び治療剤 | |
JP3248170B2 (ja) | コンドロイチン硫酸蛋白複合体含有食品 | |
AU692155B2 (en) | Method and composition for treatment of osteoporosis | |
Hale et al. | Exploring the role of progestins and phytoestrogens in menopause | |
JP4465963B2 (ja) | 高脂血症の予防または改善用組成物 | |
JPH1129488A (ja) | ピコスルファートナトリウムを含有する医薬組成物 | |
US20200129573A1 (en) | Use of euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females | |
Avioli et al. | Osteoporosis: the clinical problem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DFC4 | Cancellation of temporary protection due to refusal |